Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients

Abstract

The ART strategy on starting therapy with pegylated interferon plus ribavirin is a predictor of SVR in HIV/HCV-coinfected patients. Subjects without ART and those receiving combinations of a PI or a NNRTI with a nucleos(t)ide backbone of tenofovir or stavudine plus lamivudine respond better than those who receive other regimens.

Recent Hepatitis C Virus Infections in HIV-Infected Patients in Taiwan: Incidence and Risk Factors

“…In HCV-monoinfected patients treated with pegylated IFN plus ribavirin, the overall sustained virologic response (SVR) is 41% to 64% (12,18,25,34). In contrast, in HIV/HCV-coinfected patients treated with pegylated IFN plus ribavirin, the overall SVR in those infected with HCV genotype 1 is only 17% to 50% (4,30,31,39). While more studies are needed to identify the optimal treatments for HIV-infected patients with acute HCV infection (33), the treatment responses seen with acute HCV infection in HIVinfected populations are promising, with an overall SVR of 46% to 95%, even in patients with genotype 1 or 4 infections (1,43).…”

Nevirapine-based Antiretroviral Therapy is Associated with Lower Plasma Hepatitis C Virus Viral Load among HIV/ Hepatitis C Virus-Coinfected Patients

“…Thus, this is the first study, to our knowledge, showing an association between NVP treatment and plasma HCV viremia in the HIV/ HCV-coinfected population. Although this result must be confirmed, this finding could be important among coinfected individuals who are treated with peg-IFN plus RBV, since a low baseline HCV-RNA has a positive influence on SVR rates in these patients [1][2][3][4]. In fact, in our study, a well-known predictive factor of better response to peg-IFN plus RBV, as plasma HCV-RNA levels below 600000 IU/mL, was more common among patients taking NVP than in those subjects who were treated with other regimens.…”

“…A low plasma hepatitis C virus (HCV) load at starting pegylated interferon (peg-IFN) plus ribavirin (RBV) has been associated with a higher rate of sustained virological response (SVR) among HIV/HCVcoinfected individuals [1][2][3][4]. Due to this, the identification of factors related to lower HCV-RNA levels may help us to improve the outcome of therapy against HCV infection in this population.…”

A Brief Review on Immune Mediated Diseases

“…TDF plus lamivudine (3TC) or emtricitabine (FTC) is the first choice of NRTI combinations in coinfected individuals on treatment for HCV infection. However, there is currently little information about whether protease inhibitors (PI) and non-nucleoside reverse transcriptase inhibitors (NNRTI) which influence the rate of sustained virological response (SVR) in HIV/HCV-coinfected individuals [98][99][100].…”